Alliance Pharma PLC (LSE:APH) - Share price


Stock Report

Alliance Pharma PLC APH

Last Price
GBX100.00

Day Change
1.30|1.32%

As of 23/07/2021
17:44:18 BST | GBX
Minimum 15 Minutes Delay.

Last Close98.70p
Day Range97.37 - 100.80
Mkt Cap535.30Mil
52-Wk Range68.08 - 105.00
Yield %1.61
ISINGB0031030819
Volume1,730,364
P/E65.79
P/S0.04
P/CF0.13

Share Price

Total Returns 23/07/2021

 Chg (%)  
More ...
Alliance Pharma PLC0.60 
FTSE 100 TR GBP-0.47
 
Financials
201820192020
More ...
Income Statement
Turnover118.21135.64129.80
Operating Profit28.9237.7329.67
Net Profit18.3625.018.03
Reported EPS3.604.721.52
Balance Sheet
Current Assets58.7565.0477.24
Non Current Assets344.86342.60431.61
Total Assets403.61407.64508.85
Current Liabilities91.7224.2130.19
Total Liabilities---
Total Equity252.20274.18280.96
Cash Flow
Operating Cash Flow26.1138.9646.41
Net Change in Cash-0.337.2811.45

Regulatory News

DateAuthor Headline
17/01/2019David Brenchley UK Domestic Stocks to Weather Brexit Britain
UK stocks have been heavily sold off thanks to Brexit uncertainty, particularly those exposed to the domestic economy. But this throws up value opportunities
18/07/2018Emma Simon Investor Views: "I Should Have Ignored Warren Buffett"
Private investor Christopher Morris followed Warren Buffett's advice and invested in passive funds - but lost cash
01/02/2018David Brenchley Are Investors Wrong to Dump UK Equity Income Funds?
Investors sold £7bn worth of UK equity funds last year, but Sanlam's Philip Smeaton says there’s still lots of reasons to be excited by UK equity income
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
21/04/2021Exercise of OptionMr. Peter Jonathan Butterfield53.00205,000108,650.00
21/04/2021Sale of OptionMr. Peter Jonathan Butterfield95.4093,00088,722.00

Company Profile

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of pharmaceutical products. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from Kelo-cote brand. Geographically, it derives a majority of revenue from Europe, Middle East and Africa (EMEA).

Sector

Drug Manufacturers - Specialty & Generic

Index

FTSE AIM UK 50 , FTSE AIM 100 , FTSE AIM All-Share

Next Event 21/09/2021

Half-Yearly Results
Ratios
Comp
More ...
PER (E)65.26
Div Yld (E)1.62
PEG (E)0.00
ROCE3.15
Op Mrgn0.23
EPS Grwth-0.44
Dividends
PreviousLatest
More ...
Record Date18/12/2011/06/21
Ex-Div17/12/2010/06/21
Paid07/01/2108/07/21
Amnt0.541.07
Directors
More ...
Executive Director, Chief Executive OfficerMr. Peter Jonathan Butterfield
Non-Executive Director, ChairmanMr. David John Cook
Executive Director, Finance DirectorMr. Andrew Timothy Franklin
Non-Executive DirectorMr. Richard Crispin Morgan Jones
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.